Premenstrual Dysphoric Disorder
📧 Sign up to get email alerts when something new happens for Premenstrual Dysphoric Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Perimenstrual Symptoms and Emotional Dysregulation in Autism [NA]
Clinical trial update focusing on perimenstrual symptoms and emotional dysregulation in individuals with autism spectrum disorder and co-occ…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Study of Premenstrual Syndrome and Premenstrual Dysphoria
A completed clinical trial investigating Premenstrual Syndrome and Premenstrual Dysphoric Disorder, sponsored by the National Institute of M…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Stress, Inflammation and Neuroimaging in Major Depressive Disorder as Compared to Premenstrual Dysphoric Disorder
A recruiting study comparing stress, inflammation, and neuroimaging features in individuals with major depressive disorder versus premenstru…
-
FDA approval · 2026-03-26FDA Approved: PAROXETINE — Supplemental Application (Alembic Pharmaceuticals Inc.)
The FDA approved Alembic Pharmaceuticals Inc.'s supplemental application for paroxetine (generic). This marks approval of a generic paroxeti…
-
FDA approval · 2026-01-28FDA Approved: SERTRALINE HCL — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approves Amneal's generic sertraline hydrochloride tablet via an original ANDA. This decision enables generic competition for sertraline…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2026-01-20FDA Approved: SERTRALINE HYDROCHLORIDE — Original Application (Dr. Reddy's Laboratories Inc.)
FDA-approved original application for sertraline hydrochloride generic (Dr. Reddy's Laboratories) for multiple indications.
-
FDA approval · 2026-01-20FDA Approved: SERTRALINE HCL — Original Application (Biocon Pharma Inc.)
FDA approved Biocon Pharma Inc.'s sertraline hydrochloride generic (SERTRALINE HCL) under ANDA218342, expanding access to the generic formul…
-
FDA approval · 2026-01-15FDA Approved: FLUOXETINE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for a fluoxetine generic product manufactured by Aurobindo Pharma Limited.
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: Adapting and Piloting Acceptance and Commitment Therapy (ACT) for Severe Premenstrual Mood Symptoms [NA]
This clinical trial update notes ongoing adaptation and piloting of Acceptance and Commitment Therapy for severe premenstrual mood symptoms,…
-
FDA approval · 2025-11-20FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for sertraline hydrochloride manufactured by Aurobindo Pharma Limited. This approval covers a generi…
-
FDA approval · 2025-09-26FDA Approved: FLUOXETINE — Supplemental Application (NIVAGEN PHARMACEUTICALS, INC.)
FDA approves a supplemental application for fluoxetine hydrochloride from NIVAGEN Pharmaceuticals, enabling the marketing of a generic fluox…
-
FDA approval · 2025-09-24FDA Approved: PAROXETINE — Original Application (Alembic Pharmaceuticals Inc.)
FDA approves Alembic Pharmaceuticals Inc. Paroxetine Original Application for a generic paroxetine product.
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: Microdosing LSD in Women With Premenstrual Disorders [NA]
A clinical trial is evaluating microdosing LSD in women with Premenstrual Syndrome and Premenstrual Dysphoric Disorder; the study status is …
-
CLINICAL_TRIALS research · 2025-09-22Clinical Trial Update: Identification and Validation of Epigenetic Biomarkers of PMDD
A clinical trial update on identifying and validating epigenetic biomarkers for Premenstrual Dysphoric Disorder (PMDD), currently recruiting…
-
CLINICAL_TRIALS research · 2025-07-31Clinical Trial Update: Emotion Regulation-based Internet-delivered Cognitive Behavioural Therapy for Premenstrual Dysphoric Disorder [NA]
A clinical trial evaluating emotion regulation-based Internet-delivered cognitive behavioral therapy for Premenstrual Dysphoric Disorder is …
-
CLINICAL_TRIALS research · 2025-06-03Clinical Trial Update: Allopregnanolone and Dynamic GABA-A Receptor Plasticity in Selective Serotonin Reuptake Inhibitor Responsive Premenstrual Dysphoric Disorder [Phase 4]
Phase 4 clinical trial evaluating allopregnanolone and dynamic GABA-A receptor plasticity in SSRI-responsive Premenstrual Dysphoric Disorder…
-
CLINICAL_TRIALS trial_result · 2025-04-24Clinical Trial Update: Premenstrual Hormonal and Affective State Evaluation (PHASE) Project [NA]
A completed clinical trial update for the Premenstrual Hormonal and Affective State Evaluation (PHASE) Project investigating Premenstrual Dy…
-
CLINICAL_TRIALS research · 2025-04-06Clinical Trial Update: Pilot Study of the 'Thriving With PMDs' Program [NA]
Pilot study update for the 'Thriving With PMDs' program addressing Premenstrual Disorder and Premenstrual Dysphoric Disorder; the study is c…
-
CLINICAL_TRIALS research · 2025-04-04Clinical Trial Update: The Effect of Progressive Muscle Relaxation Exercises on Premenstrual Syndrome, Anxiety, and Tendency to Violence in Young Women [NA]
A clinical trial evaluating progressive muscle relaxation exercises for premenstrual syndrome and related anxiety or aggression in young wom…
-
FDA approval · 2025-03-13FDA Approved: PAROXETINE — Supplemental Application (NorthStar Rx LLC)
The FDA approved a supplemental application for paroxetine hydrochloride (paroxetine) as a generic product under NorthStar Rx LLC's ANDA.
-
FDA approval · 2025-02-28FDA Approved: PAROXETINE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for paroxetine hydrochloride from Zydus Lifesciences Limited, adding regulatory approval for this ge…
-
FDA approval · 2025-02-15FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (XLCare Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Sertraline Hydrochloride from XLCare Pharmaceuticals, Inc., authorizing the generic product.
-
FDA approval · 2025-02-11FDA Approved: PAROXETINE — Supplemental Application (Padagis US LLC)
FDA approved a supplemental application for paroxetine (Padagis US LLC), updating the labeling to reflect expanded indications for the antid…
-
FDA approval · 2025-01-29FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for sertraline hydrochloride (generic sertraline), authorizing the generic prod…
-
FDA approval · 2024-11-07FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Accord Healthcare, Inc.)
FDA approved a supplemental application for Accord Healthcare's sertraline hydrochloride, a generic version of sertraline, maintaining the u…